Feb 5 2010
GlaxoSmithKline today said
it had posted a strong performance in a challenging year with a return to
sales growth for the first time since 2007.
In an interview on http://www.cantos.com CEO Andrew Witty also announced
a reduction in the investment into treatments for pain and depression and a
restructuring of R&D.
He said:
"Now obviously I don't like to see anybody leave the organisation or
there to be any job losses. But the reality is that we do, from time to time,
need to look at ways in which we can improve our probability of success."
SOURCE GlaxoSmithKline
Esketamine after childbirth cuts risk of postnatal depression by three-quarters